{"DataElement":{"publicId":"4787971","version":"1","preferredName":"Minimal Residual Disease (MRD) Day 43 Induction Therapy Bone Marrow Sensitivity Value","preferredDefinition":"Sensitivity of Minimum residual disease status by flow cytometry, in bone marrow, day 43.","longName":"4787962v1.0:4787953v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"4787962","version":"1","preferredName":"Minimal Residual Disease Day 43 Induction Therapy Bone Marrow Sensitivity","preferredDefinition":"remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours._A number with no fractional part.::43_Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains._The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._The ability to respond to physical stimuli or to register small physical amounts or differences.","longName":"2452232v1.0:4787960v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2452232","version":"1","preferredName":"Minimal Residual Disease","preferredDefinition":"remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.","longName":"C3896","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D052842-7AD9-4FD3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4787960","version":"1","preferredName":"Day Integer::43 Neoadjuvant Therapy Bone Marrow Sensitivity","preferredDefinition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.:A number with no fractional part, including the negative and positive numbers as well as zero.::43:Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. :The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.:The ability to respond to physical stimuli or to register small physical amounts or differences.","longName":"4787960v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Sensitivity","conceptCode":"C25201","definition":"The ability to respond to physical stimuli or to register small physical amounts or differences.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D818-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"ONEDATA","dateModified":"2015-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D829-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for TARGET harmonization project per request by T.Davidsen. mc 4/10/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4787953","version":"1","preferredName":"MRD Sensitivity Percent Value","preferredDefinition":"Numerical representation of the sensitivity of the minimum residual disease during induction therapy.","longName":"4787953v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2414933","version":"1","preferredName":"Value","preferredDefinition":"A numerical quantity measured or assigned or computed.","longName":"C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"02772734-9BE5-6ADF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-06","modifiedBy":"ONEDATA","dateModified":"2005-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D785-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"COOPERM","dateModified":"2015-04-28","changeDescription":"Created for TARGET CDE harmonization project. mc 4/10/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5650570","version":"1","longName":"TARGET","context":"OCG","ClassificationSchemeItems":[{"publicId":"5650571","version":"1","longName":"ALL","context":"OCG"}]}],"AlternateNames":[{"name":"OCG","type":"USED_BY","context":"OCG"}],"ReferenceDocuments":[{"name":"Sensitivity of Minimum residu","type":"Preferred Question Text","description":"Sensitivity of Minimum residual disease status by flow cytometry, day 43 of induction therapy","url":null,"context":"NCIP"},{"name":"Original TARGET Question Text","type":"Alternate Question Text","description":"Sensitivity of Minimum residual disease status, day 43 of induction therapy","url":null,"context":"NCIP"},{"name":"Typical Data Entry","type":"NOTE","description":"Typical entry will be 0.01% (default) or 0.1%","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D969-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"COOPERM","dateModified":"2017-02-02","changeDescription":"Created for TARGET harmonization project per request by T.Davidsen. mc 4/10/2015 Updated definition and question text per request by Tanja. mc 12/22/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}